ENDRA Life Sciences Inc. (NASDAQ:NDRA) Short Interest Update

ENDRA Life Sciences Inc. (NASDAQ:NDRA) was the target of a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 42,119 shares, a growth of 92.3% from the June 15th total of 21,904 shares. Currently, 3.7% of the shares of the stock are short sold. Based on an average daily volume of 81,330 shares, the days-to-cover ratio is presently 0.5 days.

Analysts Set New Price Targets

Several research firms have commented on NDRA. Weiss Ratings reissued a “sell (e+)” rating on shares of ENDRA Life Sciences in a research note on Monday, April 20th. Ascendiant Capital Markets reduced their price target on shares of ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, June 1st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, ENDRA Life Sciences currently has a consensus rating of “Hold” and an average target price of $25.00.

Institutional Trading of ENDRA Life Sciences

A hedge fund recently bought a new position in ENDRA Life Sciences stock. Altium Capital Management LLC purchased a new stake in ENDRA Life Sciences Inc. (NASDAQ:NDRA) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences makes up approximately 0.9% of Altium Capital Management LLC’s holdings, making the stock its 17th largest position. Altium Capital Management LLC owned approximately 6.92% of ENDRA Life Sciences as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 1.19% of the company’s stock.

ENDRA Life Sciences Trading Down 6.1%

NDRA stock traded down $0.34 during trading hours on Thursday, hitting $5.27. 26,750 shares of the stock traded hands, compared to its average volume of 67,506. The stock has a 50-day simple moving average of $5.11 and a 200 day simple moving average of $4.58. ENDRA Life Sciences has a one year low of $2.96 and a one year high of $9.85. The company has a market cap of $6.69 million, a P/E ratio of -0.65 and a beta of -0.06.

ENDRA Life Sciences (NASDAQ:NDRA) last issued its quarterly earnings results on Friday, May 15th. The company reported ($1.09) EPS for the quarter, topping the consensus estimate of ($1.23) by $0.14. Analysts forecast that ENDRA Life Sciences will post -4.11 earnings per share for the current year.

About ENDRA Life Sciences

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.